GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrat
The industry looks set to bring the first vaccine for RSV to market in the coming year. But, which companies are leading the race, and why it would mark an important development for global health?
GSK looks set to bring the first vaccine for respiratory syncytial virus (RSV) to market in the EU, after its Arexvy shot was recommended for approval by the EMA’s human m
GSK managed to beat analysts’ revenue predictions for the first quarter of the year, despite an 8% decline in turnover pegged back by declines in COVID-19-related products